RMT Epigenomex, Inc.
RMT Epigenomex partners with biotech and pharmaceutical companies, CROs and academia to significantly reduce the time and cost of epigenetic drug discovery.
- Stage Full Product Ready
- Industry Biotechnology
- Location Buffalo, NY, US
- Currency USD
- Founded March 2014
- Employees 3
- Website rmt-epigenomex.com
Company Summary
RMT Epigenomex operates in the exciting, fast growing field of epigenetics. With an estimated $8 billion market size, epigenetics offers a more targeted drug development method. RMT provides a better tool by adding significant reductions in both time and cost of development – specifically 2 to 3 years in time savings. The company’s technology is highly scalable, allowing it to influence multiple stages of the drug development process.
Team
-
Chief Operating Officer and Chief Financial OfficerSteve has over 25 years of experience in private equity, capital markets and early-stage investing. Steve is on the Advisory Committee for Star Mountain Capital, a fund group focused on small and medium sized-companies, and has angel investments in industries including healthcare and technology. Steve holds an MBA in Finance from Fordham University & a Bachelor of Engineering degree in Electrical Engineering from Stevens Institute of Technology.
-
Joe HarrisPresident and Chief Executive OfficerJoe has over 25 years of experience in M&A and venture capital, and has a diverse background in the health industry, accounting, and law. He served in senior management positions at Glaxo SmithKline, and Eastman Kodak, where he completed over $16 Billion in M&A transactions. He previously served on the Board of Directors of PacificHealth Labs and Orthovita. He is a CPA with a JD, an MBA in Finance and a BS in Accounting from Syracuse University.
-
Chief Scientific OfficerJohn was the first to demonstrate a requirement for specific protein methylation in the cellular development of neuronal model systems. As a faculty member at SUNY at Buffalo, John spent 17 yrs teaching & writing peer-reviewed research in post-translational protein modification & methylation biology. He received a doctoral degree and two Masters degrees at Columbia University and did his postdoctoral training in cellular/molecular biology at NYU.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.